title: European Association for the Study of Diabetes 51st Annual Meeting.
authors.affiliation: Close Concerns, San Francisco, California, USA.
authors.forename: Helen X
authors.initials: HX
authors.lastname: Gao
authors.affiliation: Close Concerns, San Francisco, California, USA.
authors.forename: Emily E
authors.initials: EE
authors.lastname: Regier
authors.affiliation: Close Concerns, San Francisco, California, USA.
authors.forename: Kelly L
authors.initials: KL
authors.lastname: Close
mesh_terms: D001559:Benzhydryl Compounds / Q000627:therapeutic use; D000068896:Canagliflozin / Q000627:therapeutic use; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D005960:Glucosides / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D051297:Sodium-Glucose Transporter 2 / Q000378:metabolism; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D016896:Treatment Outcome
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D000068896:Canagliflozin; C570240:empagliflozin